Cyclacel Pharmaceuticals, Inc.
News
StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Ticker Report Investment analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) in a research note issued on Thursday. The brokerage set a "sell" rating on...\n more…
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...\n more…
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Globe Newswire Delisting or suspension action stayed pending the issuance of a final decisionBERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP...\n more…
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research A downtrend has been apparent in Cyclacel Pharmaceuticals, Inc. (CYCC) lately. While the stock has lost 13.8% over the past week, it could witness a trend reversal as a hammer chart pattern was...\n more…
Q3 2024 EPS Estimates for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Raised by Analyst
Ticker Report Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC - Free Report) - Equities researchers at Roth Capital increased their Q3 2024 earnings estimates for shares of Cyclacel Pharmaceuticals in a research note...\n more…
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St Cyclacel Pharmaceuticals ( NASDAQ:CYCC ) Second Quarter 2024 Results Key Financial Results Net loss: US$3.26m (loss...\n more…